Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
NCT05998408Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in bone marrow failure, aplastic anemia, unilineage bone marrow failure disorder, T-cell large granular lymphocytic leukemia (T-LGLL), hypoplastic myelodysplastic syndrome (hMDS), sponsored by National Heart, Lung, and Blood Institute. Started Feb 2024; status: active, not recruiting.
02
Drugs
03
Conditions
bone marrow failureaplastic anemiaunilineage bone marrow failure disorderT-cell large granular lymphocytic leukemia (T-LGLL)hypoplastic myelodysplastic syndrome (hMDS)
Beyond the preview
Go deeper on NCT05998408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998408.